Flonoltinib (TFA)

• Description:

  Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity[1].

• Product Name Alternative:

  JAK2/FLT3-IN-1 (TFA)

• UNSPSC:

  12352005

• Target:

  Apoptosis; FLT3; JAK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/flonoltinib-tfa.html

• Concentration:

  10mM

• Purity:

  98.94

• Solubility:

  H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  OCCN(C1CCN(C2=CC=C(NC3=NC=C(C)C(C4=CN(C(C)C)N=C4)=N3)C=C2F)CC1)C.O=C(O)C(F)(F)F

• Molecular Formula:

  C27H35F4N7O3

• Molecular Weight:

  581.61

• References & Citations:

  [1]Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  JAK1; JAK2; JAK3

• CAS Number:

  [2928093-29-0]